Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- Takeda Terminates Agreement with US Company on Anti-Obesity Drug Development
December 27, 2012
- Mitsubishi Chemical HD to Acquire Qualicaps
December 27, 2012
- Otsuka, Lundbeck File MAA for Abilify Once-Monthly Formulation with EMA
December 27, 2012
- Janssen Pharmaceutical Files for Additional Indication of Chronic Pain for OneDuro Patch
December 26, 2012
- Terumo Forms Alliance with AngioCare of China for Renal Denervation Catheter
December 26, 2012
- Takeda to Establish Global Customer Market Business Insights Department
December 26, 2012
- Takeda Voluntarily Recalls Ethical Version of Alinamin-F5 Injection
December 26, 2012
- Immunotherapeutic Cancer Drug Fails to Meet Primary Endpoint in PIII Study: Merck Serono
December 25, 2012
- Mortality Rate of Patients After Major Bleeds Significantly Lower with Dabigatran: BI
December 25, 2012
- Safety of Xarelto Found to Be “Consistent with Clinical Trial Data” in EPPV: Bayer Yakuhin
December 25, 2012
- Generic-only Companies Which Rely on Wholesales Worried About Decline in Their Relative Position with Wholesalers
December 25, 2012
- Increasing Competition in AD Drug Market; Sales of Over 240 Billion Yen Predicted by 2020
December 25, 2012
- Novartis Files for Approval of Combination Drug of Rasilez, CCB
December 21, 2012
- Nexium Dominates No.1, 2 Ranking in HP Market for 3rd Consecutive Month: Rep Track Survey
December 21, 2012
- Bayer Files for Approval of Radioactive Anticancer Agent in US and Europe
December 20, 2012
- Dolutegravir Filed for Approval in Europe, the US and Canada: Shionogi
December 20, 2012
- Sanofi’s JAK2 Inhibitor Improves Symptoms in Patients with MF in PII Trial
December 20, 2012
- Carsten Brunn to Take Over as President of Bayer Yakuhin in March 2013
December 20, 2012
- Eisai Transfers US Rights for Brain Tumor Treatment to Arbor Pharm
December 19, 2012
- Crestor Patent Upheld by US Court of Appeals for the Federal Circuit: Shionogi
December 19, 2012
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…